← Back to Screener
Codexis, Inc. (CDXS)
Price$2.56
Value ScoreC
Growth ScoreB
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)40.05%
Price vs S&P 500 (4W)-10.17%
VGM Score61.50
Market Capitalization$232.70M
All Metrics
Book Value / Share (Quarterly)$0.48
P/TBV (Annual)9.72x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-20.22%
Cash Flow / Share (Quarterly)$-0.24
Price vs S&P 500 (YTD)48.90%
Gross Margin (TTM)88.90%
Net Profit Margin (TTM)-40.96%
EPS (TTM)$-0.36
10-Day Avg Trading Volume0.87M
EPS Excl Extra (TTM)$-0.36
Revenue Growth (5Y)0.37%
EPS (Annual)$-0.50
ROI (Annual)-48.52%
Gross Margin (Annual)86.73%
Net Profit Margin (5Y Avg)-65.14%
Cash / Share (Quarterly)$0.72
Revenue Growth QoQ (YoY)102.15%
ROA (Last FY)-29.75%
Revenue Growth TTM (YoY)56.76%
EBITD / Share (TTM)$-0.27
ROE (5Y Avg)-61.75%
Operating Margin (TTM)-37.51%
Cash Flow / Share (Annual)$-0.26
P/B Ratio5.38x
P/B Ratio (Quarterly)3.43x
Net Income / Employee (Annual)$-301,200
EV / Revenue (TTM)3.03x
Net Interest Coverage (TTM)-137.00x
ROA (TTM)-23.72%
EV / EBITDA (TTM)387.88x
EPS Incl Extra (Annual)$-0.50
Current Ratio (Annual)3.82x
Quick Ratio (Quarterly)4.96x
3-Month Avg Trading Volume1.97M
52-Week Price Return13.27%
Revenue / Employee (TTM)$534,900
Tangible BV / Share (Quarterly)$0.74
P/S Ratio (Annual)3.31x
Asset Turnover (Annual)0.48x
52-Week High$3.87
Operating Margin (5Y Avg)-62.68%
EPS Excl Extra (Annual)$-0.50
CapEx CAGR (5Y)3.58%
Tangible BV CAGR (5Y)-26.04%
26-Week Price Return47.98%
Quick Ratio (Annual)3.53x
13-Week Price Return103.17%
Total Debt / Equity (Annual)0.79x
Current Ratio (Quarterly)5.36x
Enterprise Value$236.61M
Revenue / Share Growth (5Y)-7.04%
Asset Turnover (TTM)0.58x
Book Value / Share Growth (5Y)-26.73%
Revenue / Employee (Annual)$482,100
Inventory Turnover (Annual)5.16x
Pretax Margin (Annual)-62.41%
Cash / Share (Annual)$0.86
3-Month Return Std Dev106.67%
Gross Margin (5Y Avg)78.46%
Net Income / Employee (TTM)$-219,100
ROE (Last FY)-87.03%
EPS Basic Excl Extra (Annual)$-0.50
P/FCF (TTM)11.89x
Receivables Turnover (TTM)7.96x
Total Debt / Equity (Quarterly)0.94x
EPS Incl Extra (TTM)$-0.36
Receivables Turnover (Annual)4.76x
ROI (TTM)-36.81%
P/S Ratio (TTM)2.98x
Pretax Margin (5Y Avg)-65.02%
Revenue / Share (Annual)$0.81
Tangible BV / Share (Annual)$0.46
Price vs S&P 500 (52W)-11.09%
Year-to-Date Return57.06%
5-Day Price Return-4.12%
EPS Normalized (Annual)$-0.50
ROA (5Y Avg)-30.29%
Net Profit Margin (Annual)-62.47%
Month-to-Date Return-7.58%
Cash Flow / Share (TTM)$-1.13
EBITD / Share (Annual)$-0.42
Operating Margin (Annual)-59.30%
LT Debt / Equity (Annual)0.79x
ROI (5Y Avg)-48.16%
LT Debt / Equity (Quarterly)0.94x
EPS Basic Excl Extra (TTM)$-0.36
P/TBV (Quarterly)8.55x
P/B Ratio (Annual)2.91x
Inventory Turnover (TTM)4.59x
Pretax Margin (TTM)-40.87%
Book Value / Share (Annual)$0.56
Price vs S&P 500 (13W)94.92%
Beta2.48x
P/FCF (Annual)78.35x
Revenue / Share (TTM)$0.86
ROE (TTM)-68.09%
52-Week Low$0.96
vGradeC
gGradeB
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.10est. -0.14
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.08
4.08
4.08
4.08
Industry Peers — Industrial Chemicals(25)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CDXSCodexis, Inc. | C | B | B | $2.56 |
| LYBLyondellBasell Industries N.V. Class A | B | D | C | $64.50 |
| IFFInternational Flavors & Fragrances Inc. | C | D | C | $73.01 |
| WLKWestlake Corporation | C | C | C | $84.64 |
| NEUNewMarket Corporation | C | C | B | $790.13 |
| MEOHMethanex Corp | B | C | A | $57.62 |
| SXTSensient Technology Corporation | D | C | B | $112.19 |
| REXREX American Resources Corp. | C | B | B | $44.92 |
| BAKBraskem S.A. American Depositary Shares (Each representing Two Class A Preferred Shares) | C | D | C | $3.48 |
| GPREGreen Plains, Inc. | B | D | B | $14.97 |
| WLKPWESTLAKE CHEMICAL PARTNERS LP | A | C | B | $23.14 |
About
Codexis develops proprietary enzymatic solutions for biopharmaceutical and diagnostics manufacturing using its CodeEvolver technology platform. The company's enzymes improve production efficiency through higher yields and reduced energy consumption while enabling scaled manufacturing of RNAi therapeutics via its ECO Synthesis platform. Applications span small molecule pharmaceuticals, nucleic acid synthesis, and genomic diagnostics, with primary revenue generation from the Americas.